



5<sup>th</sup> February, 2026

The Manager,  
Listing Compliance Department,  
**National Stock Exchange of India Ltd.,**  
Exchange Plaza, Bandra Kurla Complex,  
Bandra (East), Mumbai – 400051

Corporate Office :  
406, Silver Oaks Comm. Complex,  
Opp. Arun Society, Paldi,  
Ahmedabad-380 007. Gujarat, India.  
Phone : 079-26584655  
Fax : 079-26588054  
CIN No. : L24231GJ2004PLC043861  
E-mail : info@sakarhealthcare.com  
Web : www.sakarhealthcare.com

Dear Sir,

**Sub: Outcome of Board Meeting - submission of Unaudited Financial Results & Limited Review Reports (Standalone & Consolidated) for the quarter ended on 31<sup>st</sup> December, 2025**

We refer to our letter dated 30<sup>th</sup> January, 2026 informing the date of Meeting of the Board of Directors of the Company. Please note that the Board of Directors in their meeting held today, have taken on record the Unaudited Financial Results (Standalone & Consolidated) for the quarter ended on 31<sup>st</sup> December, 2025. These results have been reviewed by the Statutory Auditors of the Company and they have provided their limited review reports dated 5<sup>th</sup> February, 2026.

We are enclosing herewith copy of the said Unaudited Financial Results (Standalone & Consolidated) and Limited Review Reports thereon.


Pursuant to SEBI Circular No. SEBI/HO/CFD/CFD-PoD-2/CIR/P/2024/185 dated 31<sup>st</sup> December 2024, please find enclosed the Integrated Filing (Financial) for the quarter ended 31<sup>st</sup> December 2025.

The Board Meeting commenced 10:00 am and concluded at 10.20 A.m.

This is as per Regulation – 33 and other applicable provisions of the SEBI (LODR) Regulations, 2015.

Thanking you.

Yours faithfully,  
**FOR SAKAR HEALTHCARE LIMITED**

  
SANJAY S. SHAH  
MANAGING DIRECTOR  
(DIN: 01515296)



Encl: As above

# Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

## STATEMENT OF STANDALONE UNAUDITED RESULTS FOR THE QUARTER ENDED ON 31<sup>ST</sup> DECEMBER, 2025

(Rs. In lakh)

Particulars	Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2025
	31-12-2025	30-09-2025	31-12-2024	31-12-2025	31-12-2024	
	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Unaudited)	(Audited)
1 <b>Revenue from operations</b>	7034.24	5756.04	4341.71	18063.90	12734.29	17758.47
2 <b>Other income</b>	50.77	121.46	29.78	211.62	113.05	131.27
<b>3 Total Income (1+2)</b>	<b>7085.01</b>	<b>5877.50</b>	<b>4371.49</b>	<b>18275.52</b>	<b>12847.34</b>	<b>17889.74</b>
<b>4 Expenses</b>						
a. Cost of Materials consumed	3854.24	2961.01	2492.61	9690.98	6943.61	9546.73
b. Purchases of stock-in-trade	-	-	-	-	-	-
c. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(300.53)	79.63	(229.37)	(201.39)	(184.46)	(1320.46)
d. Employee benefits expense	988.74	834.19	492.06	2577.89	1576.03	3164.85
e. Finance costs	177.54	152.68	129.96	544.48	434.16	853.50
f. Depreciation & amortisation expense	637.27	568.38	522.87	1762.88	1540.52	2088.22
g. Other expenses	632.51	745.82	410.57	1731.17	1003.26	1399.03
<b>Total Expenses</b>	<b>5989.77</b>	<b>5341.71</b>	<b>3818.70</b>	<b>16106.01</b>	<b>11313.12</b>	<b>15731.87</b>
<b>5 Profit before exceptional items and tax (3-4)</b>	<b>1095.25</b>	<b>535.79</b>	<b>552.80</b>	<b>2169.52</b>	<b>1534.22</b>	<b>2157.87</b>
<b>6 Exceptional items</b>	-		<b>5.14</b>	-	<b>5.14</b>	<b>5.14</b>
<b>7 Profit before tax (5-6)</b>	<b>1095.25</b>	<b>535.79</b>	<b>547.66</b>	<b>2169.52</b>	<b>1529.08</b>	<b>2152.73</b>
<b>8 Tax expense:</b>						
Current tax	183.05	100.90	91.35	374.24	255.45	366.03
Deferred tax	70.34	81.81	94.40	223.50	354.99	402.53
MAT Credit Entitlement	(183.05)	(100.90)	(91.35)	(374.24)	(255.45)	(366.03)
<b>9 Profit for the period from continuing operations (7-8)</b>	<b>1024.91</b>	<b>453.98</b>	<b>453.26</b>	<b>1946.02</b>	<b>1174.09</b>	<b>1750.20</b>
<b>10 Profit from discontinuing operations before Tax</b>	-	-	-	-	-	-
<b>11 Tax expense of discontinuing operations</b>	-	-	-	-	-	-
<b>12 Profit from Discontinuing operations (after tax) (10-11)</b>	-	-	-	-	-	-
<b>13 Profit for the period (9+12)</b>	<b>1024.91</b>	<b>453.98</b>	<b>453.26</b>	<b>1946.02</b>	<b>1174.09</b>	<b>1750.20</b>



# Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

Particulars		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2025
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	
14	<b>Other Comprehensive Income</b>						
	<i>Items that will not be reclassified subsequently to profit or loss</i>						
	Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(7.31)	(11.10)	(21.94)	(16.23)
	Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	2.03	3.09	6.10	4.52
	<i>Items that will be reclassified subsequently to profit or loss</i>						
	Income tax relating to items that will be reclassified to profit or loss		-				
	<b>Other Comprehensive Income, net of tax</b>	(2.67)	(2.67)	(5.28)	(8.01)	(15.84)	(11.71)
15	<b>Total Comprehensive Income for the period (13+14)</b>	<b>1022.24</b>	<b>451.31</b>	<b>447.98</b>	<b>1938.01</b>	<b>1158.25</b>	<b>1738.49</b>
16	Paid-up equity shares capital (Face Value per share Rs. 10/-)	2224.99	2224.99	2194.99	2224.99	2194.99	2194.99
17	Reserves excluding Revaluation Reserves						<b>26073.12</b>
18	Earnings Per Share of Rs. 10/- each (for continuing operations)						
	- Basic	4.59	2.03	2.08	8.71	5.32	7.97
	- Diluted	4.59	2.03	2.08	8.71	5.31	7.95
19	Earnings Per Share of Rs. 10/- each (for discontinued operations)						
	- Basic	-	0.00	-	-	-	0.00
	- Diluted	-	0.00	-	-	-	0.00
20	Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
	- Basic	4.59	2.03	2.08	8.71	5.32	7.97
	- Diluted	4.59	2.03	2.08	8.71	5.31	7.95



# Sakar

## Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

**Reg. Office:** Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213


**Phone:** 02717-250477 **Fax:** 02717-251621 **Email:** [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) **Web:** [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

### Notes:

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 5 <sup>th</sup> February, 2026

for SAKAR HEALTHCARE LIMITED



  
SANJAY S. SHAH  
MANAGING DIRECTOR  
(DIN : 01515296)

Date: 5<sup>th</sup> February, 2026

Place: Ahmedabad



**LIMITED REVIEW REPORT ON THE UNAUDITED STANDALONE FINANCIAL RESULTS FOR THE QUARTER  
AND NINE MONTHS ENDED DECEMBER 31, 2025**

To  
The Board of Directors  
M/s. Sakar Healthcare Limited


We have reviewed the accompanying statement of unaudited standalone financial results of Sakar Healthcare Limited for the period quarter ended 31st December 2025, being submitted by the Company pursuant to the requirements of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements), 2015, as amended ("the Listing Regulations").

This Statement, which is the responsibility of the Company's Management and approved by the Board of Directors of the Company, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.

We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement(s). A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued thereunder and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co  
Chartered Accountants  
FRN : 132059W

  
Jaimin S Shah  
Partner  
Membership No. : 138488  
UDIN : 26138488CBHABK8214

Place : Ahmedabad  
Date : 05.02.2026



**STATEMENT OF CONSOLIDATED UNAUDITED RESULTS  
FOR THE QUARTER ENDED ON 31<sup>ST</sup> DECEMBER, 2025**

(Rs. In lakh)

Particulars (Refer Notes Below)		Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2025
		31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	
1	<b>Revenue from operations</b>	7034.24	5756.04	4341.71	18063.90	12734.29	17758.47
2	<b>Other income</b>	50.77	121.46	29.78	211.62	113.05	131.27
3	<b>Total Income (1+2)</b>	<b>7085.01</b>	<b>5877.50</b>	<b>4371.49</b>	<b>18275.52</b>	<b>12847.34</b>	<b>17889.74</b>
4	<b>Expenses</b>						
	h. Cost of Materials consumed	3854.24	2961.01	2492.61	9690.98	6943.61	9546.73
	i. Purchases of stock-in-trade	-	-	-	-	-	-
	j. Changes in inventories of finished goods, work-in-progress and stock-in-trade	(300.53)	79.63	(229.37)	(201.39)	(184.46)	(1320.46)
	k. Employee benefits expense	988.74	834.19	492.06	2577.89	1576.03	3164.85
	l. Finance costs	177.54	152.68	129.96	544.48	434.16	853.50
	m. Depreciation & amortisation expense	637.27	568.38	522.87	1762.88	1540.52	2088.22
	n. Other expenses	632.51	745.82	410.57	1731.17	1003.26	1399.03
	<b>Total Expenses</b>	<b>5989.77</b>	<b>5341.71</b>	<b>3818.70</b>	<b>16106.01</b>	<b>11313.12</b>	<b>15731.87</b>
5	Profit before exceptional items and tax (3-4)	1095.25	535.79	552.80	2169.52	1534.22	2157.87
6	Exceptional items	-		5.14	-	5.14	5.14
7	Profit before tax (5-6)	1095.25	535.79	547.66	2169.52	1529.08	2152.73
8	<b>Tax expense:</b>						
	Current tax	183.05	100.90	91.35	374.24	255.45	366.03
	Deferred tax	70.34	81.81	94.40	223.50	354.99	402.53
	MAT Credit Entitlement	(183.05)	(100.90)	(91.35)	(374.24)	(255.45)	(366.03)
9	Profit for the period from continuing operations (7-8)	<b>1024.91</b>	453.98	<b>453.26</b>	<b>1946.02</b>	<b>1174.09</b>	<b>1750.20</b>
10	Profit from discontinuing operations before Tax	-	-	-	-	-	-
11	Tax expense of discontinuing operations	-	-	-	-	-	-
12	Profit from Discontinuing operations (after tax) (10-11)	-	-	-	-	-	-
13	Share of profit of associates and joint ventures accounted for using equity method	-		-	-	-	-
14	Profit for the period (9+12+13)	<b>1024.91</b>	453.98	<b>453.26</b>	<b>1946.02</b>	<b>1174.09</b>	<b>1750.20</b>
	Attributable to owner of parent	<b>1024.91</b>	453.98	<b>453.26</b>	<b>1946.02</b>	<b>1174.09</b>	<b>1750.20</b>
	Attributable to Non-controlling interests			-			-



# Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

Particulars (Refer Notes Below)	Quarter ended on			9 Months ended on (Cumulative)		Previous Year ended on 31-03-2025 (Audited)
	31-12-2025 (Unaudited)	30-09-2025 (Unaudited)	31-12-2024 (Unaudited)	31-12-2025 (Unaudited)	31-12-2024 (Unaudited)	
15 <b>Other Comprehensive Income</b>						
<i>Items that will not be reclassified subsequently to profit or loss</i>						
Re-measurement gains/(losses) on defined benefit plans	(3.70)	(3.70)	(7.31)	(11.10)	(21.94)	(16.23)
Income tax relating to items that will not be reclassified to profit or loss	1.03	1.03	2.03	3.09	6.10	4.52
<i>Items that will be reclassified subsequently to profit or loss</i>						
Income tax relating to items that will be reclassified to profit or loss		-				
<b>Other Comprehensive Income, net of tax</b>	<b>(2.67)</b>	<b>(2.67)</b>	<b>(5.27)</b>	<b>(8.01)</b>	<b>(15.84)</b>	<b>(11.71)</b>
Attributable to owner of parent	(2.67)	(2.67)	(5.28)	<b>1938.01</b>	<b>(15.84)</b>	<b>(11.71)</b>
Attributable to Non-controlling interests						
<b>16 Total Comprehensive Income for the period (14+15)</b>	<b>1022.24</b>	<b>451.31</b>	<b>447.98</b>	<b>1938.01</b>	<b>1158.25</b>	<b>1738.49</b>
Attributable to owner of parent	1022.24	451.31	447.99	1938.01	1158.25	1738.49
Attributable to Non-controlling interests						
17 Paid-up equity shares capital (Face Value per share Rs. 10/-)	2224.99	<b>2224.99</b>	<b>2194.99</b>	2224.99	<b>2194.99</b>	<b>2194.99</b>
18 Reserves excluding Revaluation Reserves						<b>26064.60</b>
19 Earnings Per Share of Rs. 10/- each (for continuing operations)	-					
- Basic	4.59	2.03	2.08	8.71	5.32	7.97
- Diluted	4.59	2.03	2.08	8.71	5.31	7.95
20 Earnings Per Share of Rs. 10/- each (for discontinued operations)						
- Basic		0.00				0.00
- Diluted		0.00				0.00
21 Earnings Per Share of Rs. 10/- each (for discontinued & continuing operations)						
- Basic	4.59	2.03	2.08	8.71	5.32	7.97
- Diluted	4.59	2.03	2.08	8.71	5.31	7.95



# Sakar

Healthcare Ltd.

[CIN: L24231GJ2004PLC043861]

Reg. Office: Block No.10-13, Village: Changodar, Sarkhej-Bavla Highway, Tal: Sanand, Dist: Ahmedabad – 382 213

Phone: 02717-250477 Fax: 02717-251621 Email: [info@sakarhealthcare.com](mailto:info@sakarhealthcare.com) Web: [www.sakarhealthcare.com](http://www.sakarhealthcare.com)

**Notes:**

1	The Company is operating only in one segment. Hence segment reporting is not given.
2	The above financial results have been prepared in accordance with the Companies (Indian Accounting Standards) Rules, 2015 (Ind AS) as amended, prescribed under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder.
3	The Company has a wholly owned subsidiary vis. M/s. Sakar Oncology Private Limited. Other than this, the Company does not have any subsidiary/ associate.
4	Provision for taxation/deferred taxation, if any, will be made at the year end.
5	Figures, wherever required, are regrouped / rearranged.
6	The above results have been reviewed by audit committee and approved by Board of Directors of Company at its meeting held on 5 <sup>th</sup> February, 2026

for SAKAR HEALTHCARE LIMITED



*Sanjay*  
SANJAY S. SHAH  
MANAGING DIRECTOR  
(DIN: 01515296)

Date: 5<sup>th</sup> February, 2026

Place: Ahmedabad

**LIMITED REVIEW REPORT ON THE UNAUDITED CONSOLIDATED FINANCIAL RESULTS FOR THE QUARTER  
AND NINE MONTHS ENDED DECEMBER 31, 2025**

To  
The Board of Directors  
M/s. Sakar Healthcare Limited

1. We have reviewed the accompanying statement of Unaudited Consolidated Financial Results of Sakar Healthcare Limited ("the Parent") and its subsidiaries (the Parent and its subsidiaries together referred to as "the Group"), and its share of the net profit/ (loss) after tax and total comprehensive income / loss of its associates and joint ventures for the quarter ended 31st December 2025 and for the period from 01.10.2025 to 31.12.2025 ("the Statement"), being submitted by the Parent pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended ("the Listing Regulations"). Attention is drawn to the fact that the consolidated figures for the corresponding quarter ended 31.12.2025 and the corresponding period from 01.04.2025 to 31.12.2025, as reported in these financial results have been approved by the Parent's Board of Directors, but have not been subjected to review.
2. This Statement, which is the responsibility of the Parent's Management and approved by the Parent's Board of Directors, has been prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013, and other accounting principles generally accepted in India and in compliance with Regulation 33 of the Listing Regulations. Our responsibility is to issue a report on the Statement based on our review.
3. We conducted our review of the Statement in accordance with the Standard on Review Engagements (SRE) 2410 "Review of Interim Financial Information Performed by the Independent Auditor of the Entity", issued by the Institute of Chartered Accountants of India. A review of interim financial information consists of making inquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Standards on Auditing and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

We also performed procedures in accordance with the circular issued by the SEBI under Regulation 33 (8) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, to the extent applicable.

4. The Statement includes the results of the following entities:

- 1) Sakar Oncology Private Limited



5. Based on our review conducted and procedures performed as stated in paragraph 3 above, nothing has come to our attention that causes us to believe that the accompanying Statement, prepared in accordance with the recognition and measurement principles laid down in Ind AS 34 prescribed under Section 133 of the Act read with relevant rules issued there under and other accounting principles generally accepted in India, has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

For J S Shah & Co  
Chartered Accountants  
FRN : 132059W

Jaimin S Shah  
Partner  
Membership No. : 138488  
UDIN : 26138488BDIMMP8276



Place : Ahmedabad  
Date : 05.02.2026

**B. STATEMENT ON DEVIATION OR VARIATION FOR PROCEEDS OF PUBLIC ISSUE, RIGHTS ISSUE, PREFERENTIAL ISSUE, QUALIFIED INSTITUTIONS PLACEMENT ETC.**

Not Applicable

**C. DISCLOSURE OF OUTSTANDING DEFAULT ON LOANS AND DEBT SECURITIES:**

Not Applicable

Sr. No.	Particulars	in INR crore
1.	<b>Loans / revolving facilities like cash credit from banks / financial institutions</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
2.	<b>Unlisted debt securities i.e. NCDs and NCRPS</b>	
A.	Total amount outstanding as on date	0
B.	Of the total amount outstanding, amount of default as on date	0
3.	<b>Total financial indebtedness of the listed entity including short-term and long-term debt</b>	0

**D. FORMAT FOR DISCLOSURE OF RELATED PARTY TRANSACTIONS (applicable only for half-yearly filings i.e., 2nd and 4th quarter)**

:Not Applicable

**E. STATEMENT ON IMPACT OF AUDIT QUALIFICATIONS (FOR AUDIT REPORT WITH MODIFIED OPINION) SUBMITTED ALONG-WITH ANNUAL AUDITED FINANCIAL RESULTS (Standalone and Consolidated separately) (applicable only for Annual Filing i.e., 4<sup>th</sup> quarter)**

:Not Applicable

for SAKAR HEALTHCARE LIMITED



*Sanjay Shah*  
SANJAY S. SHAH  
MANAGING DIRECTOR  
DIN: 01515296

Date : 5<sup>th</sup>February, 2026  
Place: Ahmedabad